NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research

        • Research Overview
        • Clinical Research Facility
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient & Public Involvement
    • Getting involved with research
    • View and register for involvement opportunities
    • Patient & Public Groups
    • Patient and Public Involvement Advisory Group
    • Diversity in Research Group
    • Oxford Blood Group
    • Case Studies
    • PPIE Strategy
    • PPIE News
    • PPI Researcher Guidance
    • Researchers: Post a PPIE opportunity
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Life-saving Vaccines > Malaria booster vaccine continues to meet WHO efficacy goal

Malaria booster vaccine continues to meet WHO efficacy goal

8 September 2022 · Listed under Life-saving Vaccines

Researchers from the University of Oxford and their partners have reported new findings from their Phase 2b trial which tested the effectiveness of a booster dose of their candidate malaria vaccine.

Child being vaccinated

The vaccine, R21/Matrix-M, had previously demonstrated high-level efficacy of 77 percent 12 months after being administered in young West African children in 2021.

In their latest findings, reported in The Lancet Infectious Diseases, they found that a vaccine booster dose one year after the primary three-dose regime maintained high efficacy against malaria, and continued to meet the World Health Organization’s goal of at least 75 percent efficacy.

The randomised, controlled, double-blind trial, which is supported by the NIHR Oxford Biomedical Research Centre, was conducted around Nanoro in Burkina Faso. A total of 450 participants aged five to 17 months were recruited, with 409 receiving the booster.

The participants were randomly assigned to three groups, with the first two groups receiving the R21/Matrix-M vaccine (with either a low dose or high dose of the Matrix-M adjuvant) as a booster and the third a rabies vaccine as the control group.

The researchers reported a vaccine efficacy of 80 percent in the higher-dose adjuvant group, and 70 percent in the lower dose adjuvant group, over 12 months of follow-up. Antibody levels were restored to similar levels as those following the primary vaccinations 28 days after the booster doses were administered.

Co-author on the paper Professor Adrian Hill, Director of the University of Oxford’s Jenner Institute and the Oxford BRC’s Theme Lead for Vaccines, said: “We are delighted to find that a standard four dose immunisation regime can now, for the first time, reach the high efficacy level over two years that has been an aspirational target for malaria vaccines for so many years.”

Read More.

← Human trials of aerosol-based TB vaccine begin

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2023 NIHR Oxford Biomedical Research Centre